This is a global, randomized, Phase I/II study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary food effect of single-agent ITU512 in adult healthy participants, and safety, tolerability, PK, PD, and efficacy of ITU512 in adolescent and adult patients with sickle cell disease (SCD). The study consists of a first-in-human Phase I study (Part 1) in healthy participants, and a Phase II study (Part 2) in patients with SCD.
Part 1 will comprise of Part 1A, Part 1B, and Part 1C. Part 2 will include Part 2A and 2B and may also include an extension part (Part 2C).
Age
12–55
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Part 1 (Healthy participants)
Healthy male participants and female participants of non-childbearing potential between 18-55 years of age
In good health as determined by the investigator's assessment of medical history, physical examination, vital signs, ECG, and laboratory tests
Participants must weigh at least 50 kg at screening and first baseline (admission) and must have a body mass index (BMI) within the range of 18.0-32.0 kg/m2 inclusive.
Part 2 (Sickle Cell Disease)
\- Male and female participants with a diagnosis of sickle cell disease
You may not be if
Part 1 (Healthy participants)
QTcF ≥ 450 msec (as a mean value of triplicates)
History of arrhythmias
History of significant illness which has not resolved within two (2) weeks prior to initial dosing
Women of child-bearing potential (WOCBP)
Part 2 (Sickle Cell Disease)
Current use of hydroxyurea/hydroxycarbamide (HU/HC)